Merrimack Pharmaceuticals Inc financial data

Industry
Pharmaceutical Preparations
Location
One Broadway, 14 Th Floor, Cambridge, MA
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q1 2024 - May 15, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.26K % -63.6%
Debt-to-equity 8.63 % +190%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 14.5M shares +1.94%
Common Stock, Shares, Outstanding 14.5M shares +1.94%
Entity Public Float 130M USD 0%
Common Stock, Value, Issued 1.35M USD +0.15%
Weighted Average Number of Shares Outstanding, Basic 14.5M shares +1.4%
Weighted Average Number of Shares Outstanding, Diluted 14.5M shares +1.4%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 2.26M USD +3.48%
Operating Income (Loss) -2.26M USD -10.5%
Nonoperating Income (Expense) 925K USD +32.4%
Earnings Per Share, Basic 13.9 USD/shares
Earnings Per Share, Diluted 13.9 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 234M USD +1107%
Cash, Cash Equivalents, and Short-term Investments 244M USD +1158%
Assets, Current 244M USD +1145%
Other Assets, Noncurrent 3K USD -57.1%
Assets 244M USD +1144%
Accounts Payable, Current 168K USD +88.8%
Accrued Liabilities, Current 161K USD +17.5%
Liabilities, Current 22.7M USD +4797%
Liabilities 22.7M USD +4797%
Retained Earnings (Accumulated Deficit) -347M USD +36.6%
Stockholders' Equity Attributable to Parent 222M USD +1056%
Liabilities and Equity 244M USD +1144%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.31M USD -269%
Net Cash Provided by (Used in) Financing Activities 1.49M USD +730%
Net Cash Provided by (Used in) Investing Activities 228M USD +163929%
Common Stock, Shares Authorized 30M shares 0%
Common Stock, Shares, Issued 14.5M shares +1.94%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 228M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 234M USD +1107%
Deferred Tax Assets, Valuation Allowance 250M USD +0.11%
Deferred Tax Assets, Gross 250M USD +0.11%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 200M USD
Deferred Tax Assets, Operating Loss Carryforwards 65.2M USD +1.65%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Preferred Stock, Shares Outstanding 0 shares
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%